Cheaper and more effective test available for women following pre-cervical cancer treatmentNovember 01, 2012
Testing women to see if they are cured of HPV (the virus that can cause genital warts and cervical cancer) following treatment for abnormal cells on the surface of the cervix is more effective and cheaper than cytology testing (cervical screening) alone, suggests a study published on bmj.com today. A second study published today, finds that the risk of cervical cancer after treatment and cytological follow-up for abnormalities remains about four times higher than in women with normal cytology tests, regardless of age and stage of abnormality.
In England, cervical screening is recommended every three years for women aged 25-49 and every five years for women aged 50-65 years.
Cervical intraepithelial neoplasia or CIN are pre-cancerous lesions on the surface of the cervix that can develop into cervical cancer if left untreated. After treatment for high grade CIN, guidelines in the UK previously recommended annual cytology for at least 10 years. After low grade CIN, cytology is recommended at six, 12 and 24 months, and if all results are negative then women can resume routine screening.
Previous studies are inconsistent about whether or not HPV testing as 'test of cure' is more effective or cost-effective than cytology testing alone. So far, only two published studies have been identified, one concluding that it was potentially a cost-effective strategy and the other that it increased costs and added little or no improvement to life expectancy.
Authors from the London School of Hygiene & Tropical Medicine and Cancer Council, NSW in Australia therefore carried out a study to assess the cost-effectiveness of HPV testing after treatment for CIN. They took data from six sites across England that returned women to routine screening after a single negative HPV test result at six months.
Almost two-thirds (63%) of women were aged 35 or younger and one in 10 had been treated for CIN stage 1. The rest were treated for CIN stages 2 or 3.
Cytology only follow-up after treatment for CIN resulted in 29 reoccurring cases of CIN stage 3 per 1000 women over 10 years. The HPV 'test for cure' averted around eight additional cases over this time. The cytology only follow-up estimated cost is £358,222 per 1,000 women with HPV 'test of cure' costing £348,834, saving approximately £9,388 per 1000 women treated.
The authors say that early use of HPV testing after treatment averts more cases of CIN stage 3 and is cost-saving compared to current practice because it is more effective at early detection of women who are at risk of recurrent disease in future. They add that HPV testing results in fewer colposcopies (a detailed examination of the cervix) over 10 years than cytology only follow-up, and a higher proportion of colposcopies resulted in re-treatment - an important reduction in the burden of follow-up on women, and also on the health system.
They conclude that HPV 'test of cure' is more effective and less costly than the annual cytology follow-up over 10 years. HPV testing performed six months after treatment effectively "distinguishes women at future risk of serious recurrent cervical disease and supports the full scale implementation of HPV testing as a test of cure after treatment of CIN". They add however that there is a need for ongoing monitoring and evaluation of the long term safety of these strategies.
In the second study, researchers compared the risk of cervical cancer in 38,956 women in the Netherlands who returned to routine screening after completing their cytological post-treatment follow-up for CIN with women with normal cytology results.
They found a fourfold increased risk in treated women (35 cases per 100,000 woman years) compared with 6 cases per 100,000 woman years for untreated women, regardless of age and grade of CIN.
They say their results "have implications for women treated for cervical intraepithelial neoplasia, although how the excess risk could be decreased is not straightforward."
In an accompanying editorial, clinicians from the departments of pathology and epidemiology at the VU Medical Centre in Amsterdam also suggest that cytology and HPV testing at six and 24 months should be sufficient. They agree that post-treatment surveillance should aim at detecting HPV and question whether short-term surveillance "constitutes sufficient follow-up before patient return to the usual screening programme". They suggest there is no evidence to long term intensive monitoring and that "current guidelines [should] be modified".
Related Cervical Cancer Articles:
A new review looks at cervical cancer screening in the era of HPV vaccination.
Duke University researchers have developed a handheld device for cervical cancer screening that promises to do away with uncomfortable speculums and high-cost colposcopes.
While current guidelines indicate that cervical cancer screening can be stopped for average risk patients after age 65, many women lack the appropriate amount of screening history to accurately assess their risk.
Navkiran Shokar, M.A., M.P.H, M.D., has received nearly $1.5 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to reduce the burden of cervical cancer in West Texas.
Fewer than three out of five women with cervical cancer received guideline-based care, a new study finds.
A new analysis reveals that for most women, the risk of dying from cervical cancer is higher than previously thought.
Women may only need cervical cancer screening every 5-10 years -- instead of every three years, as currently recommended -- and may be able to start the screenings later in life, according to Harvard T.H.
A new study from the University of Illinois confirms a link between Pap smear screenings and a lower risk of developing cervical cancer in women over age 65.
Lupus confirmed as risk factor for cervical cancer
Cervical cancer is an 'enormous burden' for Latin-American society, and the third leading cause of cancer deaths among women in the region, say Dr.
Related Cervical Cancer Reading:
by Jaime G. de la Garza-Salazar (Editor), Flavia Morales-Vásquez (Editor), Abelardo Meneses-Garcia (Editor)
This book provides readers with a thorough review on cervical cancer, treatment guidelines and emerging therapies available for the disease. It reviews the epidemiology clinical features, diagnosis, and medical management of cervical cancer.
Given the increasing need for preventive strategies, treatment optimization with collaborative and integrative work, this book improves the actual and integral knowledge in this neoplasm. Given the high prevalence of this disease in Latin America, this is an important text for clinicians in this region.
This book outlines the state of... View Details
Johns Hopkins Patients' Guide to Cervical Cancer
by Colleen C. McCormick (Author), Robert L. Giuntoli II (Author)
Johns Hopkins Patients' Guide to Cervical Cancer is a concise, easy-to-follow "how to" guide that puts you on a path to wellness by explaining cervical cancer treatment from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and performs the task of putting together your plan of care in layman's terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment. View Details
Choose This not That for Cervical Cancer
by Personal Remedies (Author)
Choose This not That for Cervical Cancer. This colorful book provides comprehensive and actionable nutrition guidelines for how to reduce your risk, prevent and combat Cervical Cancer (CC). If you rather tackle health issues and risks through proper nutrition and lifestyle changes as opposed to prescription drugs and other typical medical treatments, then this book is for you.
Here are the highlights and what makes this publication unique and different from your other options:
A look-up table for over 800 different types of food and their suitability for CC Health... View Details
My Cancerous Hoo-Hah: A Story of Cervical Cancer
Do you know what it’s like to go step-by-step through cervical cancer treatment? The only way to get through it is with laughter, good friends, and an occasional glass of wine. The blog, diary and social media posts in this collection detail every horrible, humiliating and humorous aspect of seeking medical treatment for a woman’s issue in an industry filled mainly by men. The Internet contains many forums for those seeking answers to medical questions, but most of these quickly degenerate into questions from the lovelorn or cries for help from anyone with an unknown itch. What you want... View Details
Cervical Cancer: From Etiology to Prevention (Cancer Prevention-Cancer Causes)
by Thomas E. Rohan (Editor), Keerti V. Shah (Editor)
The last few years have seen enormous progress in terms of our understanding of the etiology and pathogenesis of cervical cancer (particularly with respect to the role of human papillomaviruses), and this has opened up new avenues for prevention. Additionally, there have been further refinements of existing technologies for cervical cancer control. To read about the state of the art on cervical cancer, health professionals have to locate individual articles and reviews of specific topics. In recognition of this, we propose to produce a book that will bring together in one place reviews of the... View Details
Not Quite a Cancer Vaccine: Selling HPV and Cervical Cancer
by Samantha D. Gottlieb (Author)
In Not Quite a Cancer Vaccine, medical anthropologist S.D. Gottlieb explores how the vaccine Gardasil—developed against the most common sexually-transmitted infection, human papillomavirus (HPV)—was marketed primarily as a cervical cancer vaccine. Gardasil quickly became implicated in two pre-existing debates—about adolescent sexuality and pediatric vaccinations more generally.
Prior to its market debut, Gardasil seemed to offer female empowerment, touting protection against HPV and its potential for cervical cancer. Gottlieb questions the marketing pitch’s vaunted... View Details
Cervical Cancer (Diseases and Disorders)
by Kris Hirschmann (Author)
Discusses cancer of the cervix, including the role of human papillomaviruses in causing the illness, treatments, and the controversy over vaccinating preteen girls against a sexually-transmitted disease to lower the chance of getting cancer. View Details
Cell War Notebooks: My Journey with Cervical Cancer
by Julie Forward DeMay (Author)
Beautifully written, heartwarming, and passionate, Cell War Notebooks draws us into a world many are familiar with. Recorded as a blog during a period of seven months, Cell War Notebooks is both a sensitive and brutally honest account of life with cancer. An essential read for people coping with the disease, and for the family and friends who support and love them, it's the deeply motivating story of a battle Julie Forward DeMay is determined to win. One of few memoirs written about cervical cancer, her inspirational journey was published for many reasons, one of which was to create a general... View Details
100 Questions & Answers About Cervical Cancer
by Don S. Dizon (Author), Michael L. Krychman (Author), Paul DiSilvestro (Author)
The only text to provide both the patient?fs and doctor?fs views, 100 Questions & Answers About Cervical Cancer aims to provide a much needed primer for patients and their families and aims to address the questions most relevant to a woman following a diagnosis of pre-invasive changes or invasive cervical cancer. This text gives up-to-date, authoritative, practical answers to your questions about cervical cancer; not only the diagnosis and treatment of the disease, but also female survivorship. This is an invaluable resource for anyone coping with the physical and emotional turmoil of this... View Details
EARLY DETECTION OF CERVICAL CANCER: PAP SMEAR or COLPOSCOPY: ?Correlation of Cytological, Colposocpical and Histopathological findings in patients with Cervical lesions"
by MINAKSHI SARDHA (Author), ARSHAD ANJUM (Author)
Cancer cervix is the 2nd most common cancer in women accounting for 68.5% of all gynecological malignancies.The estimated new cancer cervix cases per year are 500,000 of which 79% occur in the developing countries.Cervical dysplasia does not cause many symptoms;therefore, regular screening and early diagnosis are important. The single most important step that a woman can take to prevent cervical cancer is a pap smear, which is a gentle scraping at the cervix during a gynecological examination.To judge the merits of a pap smear,Colposcopy provides a technique for visualization of cervix and... View Details